
Seaport Therapeutics


Seaport Therapeutics, founded in 2024, is a biopharmaceutical company with the ambition of revolutionizing the treatment of neuropsychiatric disorders through innovative therapies. Its proprietary technology, Glyph™, optimizes the oral absorption of drugs while minimizing side effects, notably hepatotoxicity.
With its solid financing, Seaport Therapeutics is ideally positioned to accelerate the development of cutting-edge solutions and make a significant contribution to improving mental and neurological health.